Stock Groups

Moderna Jumps as Trial for Experimental HIV Vaccine Begins -Breaking

by Mike Robinson

[ad_1]

© Reuters

Sam Boughedda

Investing.com — Moderna Inc (NASDAQ:) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine, the company said Monday. 

Moderna shares rose by 17% following the announcement.

Moderna stated in a press release, that Phase 1, an open-label multicenter randomized trial, is being conducted to evaluate the safety and immunogenicity experimental HIV trimer vaccines.

According to the company, these mRNA vaccines are safe for HIV-uninfected people and produce neutralizing antibodies.

About 100 HIV-negative people aged between 18 and 55 will be enrolled in the trial sponsored and funded at the National Institutes of Health by the Division of AIDS.

The development of a vaccine program that causes sustained protection against HIV in human beings has proved difficult. Moderna president Stephen Hoge said that Moderna believes that mRNA is a way to tackle this problem.

 

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]